Vertex Pharmaceuticals: Analysts Bullish, Shorts Retreat Before Q3 Print

Options traders have grown modestly more cautious ahead of VRTX's November 2 results, even as short sellers continue to trim their positions.

The put/call ratio has drifted up to 0.97, about 1.2 standard deviations above its 20-day average of 0.92. That places it well above where it spent most of September, though still far from the 52-week high of 1.27. The move is mild rather than alarming, suggesting investors are buying a degree of downside protection without making a strong directional call. The stock itself has been largely unmoved, adding about 2% over the past month to close at $540, a touch below where most analysts are targeting it.

Short sellers are retreating, not pressing. Short interest dropped 5.6% over the past week to 1.7% of the free float, with the decline accelerating in the final few days of October. That follows a sustained one-month decline of around 8%. Borrowing costs are negligible at 0.41%, and availability is effectively unlimited, leaving no friction for anyone who wants to establish or cover a position. The short case here is thin in both conviction and scale.

The analyst community leans constructively. Targets from firms including UBS, Morgan Stanley, Barclays, and JP Morgan all sit above the current price, with a Morgan Stanley Overweight carrying the highest published target at $665. RBC Capital raised its target to $576 in early October while maintaining Outperform. The consensus is officially "hold" by count, reflecting a handful of cautious voices, but the weight of recent activity has been on the bullish side. The debate centres on whether Trikafta is approaching a revenue ceiling: bears point to the product running slightly below consensus in recent quarters, and flag pipeline risk around povetacicept and inaxaplin. Bulls respond that the cystic fibrosis franchise faces no near-term competitive threat, and that a multi-drug pipeline gives the company multiple paths to the $28 billion revenue figure some project by 2035.

One supplementary data point adds colour. Medicaid prescriptions tracked by the Centers for Medicare and Medicaid Services rose 59% against Q1 last year, and have now grown for four consecutive quarters. No measured lead between this series and Vertex's reported figures has been established, so the streak cannot be read as a forecast for the print. It does, however, confirm that uptake in the government-payer channel has been consistent.

Capital Research and Management holds just over 20% of shares, making it by far the dominant institutional voice. BlackRock and Vanguard together account for another 17%. With the register this concentrated among passive and long-only holders, the print is less likely to trigger forced selling and more likely to be judged on whether Trikafta revenue lines up with consensus and whether pipeline commentary on povetacicept moves the needle on long-term estimates. The stock's roughly 1% gain on the week compares with a median of about 3.4% for its closest correlated peers, a gap that leaves it with something to prove on Monday.